Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib (Q36677456)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on December 2006

Language	Label	Description	Also known as
English	Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib	scientific article published on December 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

chronic myeloid leukemia

0 references

Hagop Kantarjian

2

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Jorge Eduardo Cortes

3

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

author name string

Alfonso Quintás-Cardama

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

language of work or name

0 references

publication date

1 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Future Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

655-665

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Cell cycle targets of Ras/Raf signalling

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Src family tyrosine kinases and growth factor signaling

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Identifiers

10.2217/14796694.2.6.655

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36677456&oldid=1645816400"